Growth Metrics

PAVmed (PAVM) Amortization of Deferred Charges (2017 - 2018)

PAVmed's quarterly Amortization of Deferred Charges came in at $505848.0 in Q3 2018, up 65.45% quarter-over-quarter from $305734.0 in Q2 2018.

PAVmed has reported Amortization of Deferred Charges for 2 years, with the latest figure at $505848.0 in Q3 2018.

  • For the quarter ending Q3 2018, Amortization of Deferred Charges changed N/A year-over-year to $505848.0; the trailing twelve-month figure through Sep 2018 stood at $1.3 million (changed N/A YoY), and the FY2017 full-year result was $347601.0, changed N/A from the prior year.
  • Amortization of Deferred Charges for Q3 2018 stood at $505848.0, up from $305734.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $505848.0 in Q3 2018, with the low at $172959.0 in Q4 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 PAVmed 4.15 Mn -9.02 Mn -703,000.00

Historic Data

Download Data 🔒
DateValue
Sep 30, 2018 505,848.00
Sep 30, 2018 505,848.00
Jun 30, 2018 305,734.00
Jun 30, 2018 305,734.00
Mar 31, 2018 305,733.00
Mar 31, 2018 305,733.00
Dec 31, 2017 172,959.00
Dec 31, 2017 172,959.00